Showing results (311-320 of 335) with videos related to

Sort By:
Pageof 34
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2024
Expert consensus on workflow of PET/CT with long axial field-of-viewGuobing Liu, Yushen Gu, Martina Sollini, et al.
EMBO Molecular Medicine|March 5, 2016
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markersMarc Suárez-Calvet, Gernot Kleinberger, Miguel Ángel Araque Caballero, et al.
Theranostics|September 15, 2021
Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulationGloria Biechele, Tanja Blume, Maximilian Deussing, et al.
Medical Image Analysis|April 3, 2026
Dose-aware diffusion model for 3D PET image denoising: Multi-institutional validation with reader study and real low-dose dataHuidong Xie, Weijie Gan, Reimund Bayerlein, et al.
Annals of Neurology|February 27, 2019
Metabolic patterns across core features in dementia with lewy bodiesSilvia Morbelli, Andrea Chincarini, Matthias Brendel, et al.
Frontiers in Aging Neuroscience|April 18, 2022
Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves CognitionTanja Blume, Maximilian Deussing, Gloria Biechele, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 2, 2021
Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium projectMatteo Bauckneht, Andrea Chincarini, Matthias Brendel, et al.
Nature Neuroscience|January 9, 2019
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoESamira Parhizkar, Thomas Arzberger, Matthias Brendel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 27, 2020
In Vivo Assessment of Neuroinflammation in 4-Repeat TauopathiesCarla Palleis, Julia Sauerbeck, Leonie Beyer, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|April 16, 2019
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility SystemThilo van Eimeren, Angelo Antonini, Daniela Berg, et al.
Pageof 34